E-ISSN 2148-5607
RELATED ARTICLES
Editorial
Daily consensus interferon (CIFN) monotherapy in non-responders or relapsers to a previous interferon regime: One year follow-up after 48 weeks of treatment
(Turk J Gastroenterol 2006; 17: 35-39)
The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients
(Turk J Gastroenterol 2006; 17: 94-98)
Predictive value of proliferating cell nuclear antigen index in response to interferon treatment in patients with chronic viral hepatitis B and C
(Turk J Gastroenterol 2001; 12: 89-94)
Transmission routes of chronic hepatitis C and their relation to HCV genotypes
(Turk J Gastroenterol 2010; 21: 396-400)
DOI: 10.4318/tjg.2010.0126
HCV genotypes in HCV related chronic hepatitis in Southeast Anatolia
(Turk J Gastroenterol 1999; 10: 249-252)
Original Article
Simple non-invasive markers as a predictor of fibrosis and viral response in chronic hepatitis C patients
(Turk J Gastroenterol 2012; 23: 538-545)
DOI: 10.4318/tjg.2012.0358
AST-platelet ratio index, Forns index and FIB-4 in the prediction of significant fibrosis and cirrhosis in patients with chronic hepatitis C
(Turk J Gastroenterol 2011; 22: 279-285)
DOI: 10.4318/tjg.2011.0213
Can eicosapentaenoic acid maintain the original ribavirin dose or affect the response during the treatment course of chronic hepatitis C virus (HCV) patients?
(Turk J Gastroenterol 2016; 27: 55-61)
DOI: 10.5152/tjg.2015.150280
The predictive value of noninvasive serum markers of liver fibrosis in patients with chronic hepatitis C
(Turk J Gastroenterol 2016; 27: 156-164)
DOI: 10.5152/tjg.2015.150449
The association between insulin resistance and hepatic fibrosis in patients with chronic hepatitis C: An observational, multicenter study in Turkey
(Turk J Gastroenterol 2014; 25: 546-552)
DOI: 10.5152/tjg.2014.7829
Liver - Original Article
Real-life results of treatment with ombitasvir, paritaprevir, dasabuvir, and ritonavir combination in patients with chronic renal failure infected with HCV in Turkey
(Turk J Gastroenterol 2019; 30: 331-335)
DOI: 10.5152/tjg.2018.18269
Assessing the outcome of patients with liver cirrhosis during hospital stay: A comparison of lymphocyte/monocyte ratio with MELD and Child-Pugh scores
(Turk J Gastroenterol 2018; 29: 308-315)
DOI: 10.5152/tjg.2018.17631
Does steatosis affect the performance of diffusion-weighted MRI values for fibrosis evaluation in patients with chronic hepatitis C genotype 4?
(Turk J Gastroenterol 2017; 28: 283-288)
DOI: 10.5152/tjg.2017.16640
Diagnostic value of combined serum biomarkers for the evaluation of liver fibrosis in chronic hepatitis C infection: A multicenter, noninterventional, observational study
(Turk J Gastroenterol 2018; 29: 464-472)
DOI: 10.5152/tjg.2018.16597
Poster
Real-world efficacy, safety and clinical outcomes of ombitasvir/ paritaprevir/ ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: Turkey experience
(Turk J Gastroenterol 2019; 30: 10-15)
DOI: 10.5152/tjg.2019.07
Successfully treatment of chronic hepatitis C with direct-acting antiviral agents: a single center experience
(Turk J Gastroenterol 2019; 30: 34-34)
DOI: 10.5152/tjg.2019.20
Prevalence of the potential drug-drug interactions between pangenotypic direct-acting antivirals and the concomitant medication with patients with chronic hepatitis C virus infection
(Turk J Gastroenterol 2019; 30: 43-45)
DOI: 10.5152/tjg.2019.28
Key Words
Authors
All
Reviewer's Corner
Author’s Corner
Survey
AVES | Copyright © 2019 Turkish Society of Gastroenterology | Latest Update: 04.07.2019